
|Articles|February 27, 2006
Par launches advanced formulation of Megace ES
Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.
Advertisement
Par launches advanced formulation of Megace ES
Par Pharmaceutical has launched an advanced formulation of megestrol acetate, Megace ES 625 mg/5 ml (megestrol acetate) oral suspension. Megace ES is indicated for the treatment of anorexia, cachexia, or a significant, unexplained weight loss in patients with a diagnosis of AIDS.
To see more Hot off the Press news articles, click here
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
New Study Finds Compounded GLP-1s Remain Robust Despite End of Shortages
2
Once Weekly Oral HIV Regimen Maintains Suppression Through Week 48
3
ICER Report Finds GLP-1s Are Cost-Effective But Warns of Budget Strain
4
Postpartum Mothers Favor Bedtime Stopping Rule Over Stricter Chrononutrition Approaches
5




























